Facebook
Twitter
LinkedIn
ForwardTitle
Category
Credits
Event date
Cost
- CMHC
- 1.25 ACPE Pharmacy
- 1.25 AMA PRA Category 1 Credit™
- 1.25 ANCC
- 1.25 Participation
$0.00
Welcome to our micro-module webcast on the challenges of managing chronic kidney disease (CKD) and diabetes. After diagnosis, slowing CKD progression in type 2 diabetes (T2D) continues to pose a major challenge. Although new therapies, such as sodium-glucose cotransporter-2 (SGLT-2) inhibitors, have emerged, residual morbidity and mortality persist. Additional strategies are required to slow kidney disease progression, especially targeting inflammation and fibrosis.
- CMHC
- 4.00 Participation
$0.00
Dr. Ronald M. Krauss, MD, Professor of Medicine at UCSF and Adjunct Professor of Nutritional Sciences at UC Berkeley, and Nina Teicholz, PhD, author and science journalist, co-organized this course on Dietary Approaches to Reversing Type 2 Diabetes. The course is offered as a legacy to the late Dr. Sarah Hallberg, a pioneer in the research and promotion of putting type 2 (T2) diabetes into remission—or “reversal” of the disease, as she preferred to describe the process of restoring average blood sugar (A1c) to normal levels while eliminating the need for all or most medications.
- CMHC
- 1.25 ACPE Pharmacy
- 1.25 AMA PRA Category 1 Credit™
- 1.25 ANCC
- 1.25 Participation
$0.00
Welcome to our webcast on worsening heart failure. Heart failure remains one of the most challenging conditions to manage, with worsening heart failure being a critical area where suboptimal outcomes persist. While foundational therapies such as beta-blockers, ACE inhibitors, mineralocorticoid receptor antagonists, and ARNIs remain integral to heart failure management, advances in our understanding of heart failure pathophysiology have opened the door to newer, innovative therapeutic options, such as SGLT-2i, sCG stimulators and SGLT1/2 inhibitors.
- LivDerm
- TME
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation
$0.00
Various gaps in the management of psoriasis patients with skin of color (SOC) persist due to a lack of training on SOC and inherent barriers to care. As a result, psoriasis patients with SOC are often misdiagnosed, experience more severe disease, and experience more disease burden. Recent clinical trial data supports the need for nuanced care when treating psoriasis patients with SOC using systemic agents. It is important that clinicians are able to identify treatment barriers and develop strategies to address these barriers and personalize care.
- LivDerm
- TME
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation
$0.00
BTK inhibitors have demonstrated great promise for addressing various treatment challenges for chronic urticaria patients by improving symptom control and more effective targeting of disease pathways.
- CMHC
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 CDE
- 1.00 Participation
$0.00
Metabolic dysfunction-associated steatohepatitis (MASH) is a complex condition rooted in metabolic disturbances and often coexists with obesity, prediabetes, type 2 diabetes, and cardiovascular disease. Stemming from metabolic dysfunction-associated steatotic liver disease (MASLD), MASH is closely linked to cardiometabolic risk factors and pre-existing cardiovascular conditions. MASH is a gradually advancing and often asymptomatic liver disease that necessitates early detection and diagnosis.
- CMHC
- 0.50 ACPE Pharmacy
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC
- 0.50 CDE
- 0.50 Participation
$0.00
This clinical brief was developed from a presentation at the 19th CMHC Annual Congress held from October 17-19, 2024 in Boston, MA. The session, “Evolving Therapies in Dyslipidemia and ASCVD Risk Reduction: Putting It All Together in High-Risk Patients,” was presented by Dr. Pamela B. Morris, Professor of Medicine, Cardiology from The Medical University of South Carolina, Charleston, SC, supported by an educational grant from Esperion Therapeutics.
- LivDerm
- TME
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC
- 0.50 Participation
$0.00
Chronic spontaneous urticaria (CSU) has unpredictable symptoms without an obvious external cause; however, the symptoms of CSU, such as hives, itching and swelling, mimic an allergic reaction, and there is often significant time spent finding an external trigger. Despite current treatment options for CSU, treatment resistance and poor symptom control remain significant challenges; only 40% of patients achieve complete symptom control with standard therapy.
- LivDerm
- TME
- 0.75 AAPA Category I CME
- 0.75 AMA PRA Category 1 Credit™
- 0.75 ANCC
- 0.75 Participation
$0.00
Severe alopecia areata (AA) causes a significant disease burden impacting multiple aspects of patients’ health, quality of life, and daily functioning. New treatment options, including Janus kinase (JAK) inhibitors, are becoming available, but diagnosis and management can be challenging, especially for pediatric patients and those with skin of color.
- LivDerm
- TME
- 0.50 AAPA Category I CME
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC
- 0.50 Participation
$0.00
While corticosteroids hold a valuable place in the therapeutic toolkit for atopic dermatitis, psoriasis, seborrheic dermatitis, and similar conditions, targeted topical therapies may offer better options for individualized care. Non-steroidal targeted therapies allow for better efficacy, improved safety, long-term use, and treatment of sensitive regions of the skin. Health care professionals require expert guidance on clinical data for new and emerging targeted topical therapies and strategies for utilizing them to improve outcomes in adult and pediatric patients.